Venetoclax was the first BCL-2-selective BH3-mimetic to achieve FDA approval for Chronic Lymphocytic Leukaemia (CLL), and thus represents a milestone in small molecules targeting PPIs (Roberts and Huang, 2017). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.